Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

informatics > Investigational Drug > Flashcards

Investigational Drug Flashcards

1
Q

Any experiment in which a drug is
administered or dispensed to one or more
human subjects.

A

Clinical
Investigation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

A drug, antibiotic, or biologic that is used in
a clinical investigation.

A

Investigational
New Drug (IND)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The label of an
investigational drug must bear the
statement:

A

“Caution: New Drug—Limited
by Federal (or U.S.) law to investigational
use.”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

IND application is a submission to the FDA containing

A

chemical information, preclinical data, and a detailed description of the planned clinical
trials

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

An IND for which the sponsor is usually
either a corporate entity or one of the
institutes of the National Institutes of Health
(NIH).

A

Commercial IND

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Strictly for research purposes, done to prove
a theory, improve an existing treatment
institutes/academe

A

Research IND

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

The individual responsible for initiating the

clinical trial at the study site.

A

Investigator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

An individual who participates in a clinical
investigation (either as the recipient of the
investigational drug or as a member of the
control group).

A

Subject

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

A standard for the design, conduct,
monitoring, analyses, and reporting of
clinical trials that provides assurance that
the results are credible and accurate, and
that the rights of study subjects are
protected

A

Good Clinical
Practice (GCP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

A committee of reviewers that is responsible
for ensuring the protection of the rights,
safety, and well-being of human subjects
involved in a clinical investigation.

A

Institutional
Review Board
(IRB)/Institutiona
l Ethics
Committee (IEC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

First major attempt of drug regulation

A

Import Drug Act of 1848

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

provided for the inspection, detention and
destruction or reexport of imported drug
shipments that failed to meet standards

A

Import Drug Act of 1848

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

drugs not to be mislabeled or adulterated and
must meet recognized standards for strength
and purity.

A

Pure Food and Drugs Act (1906)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

safety of drugs, and be proven through testing
before they can be marketed

A

Food, Drug and Cosmetic Act of 1938

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

when was Food, Drug and Cosmetic Act of 1938 created

A

June 25,1938

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

creation of OTC and Rx drugs

A

Durham and-Humphrey Amendment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Authorized that prescriptions can be refilled

A

Durham and-Humphrey Amendment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Caution: Federal law prohibits dispensing
without prescription

A

Durham and-Humphrey Amendment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

manufacturer had to demonstrate efficacy, and
safety of drug prior to marketing (because of
phocomelia secondary to Thalidomide)

A

Kefauver-Harris Drug Amendment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

medication used to
treat motion sickness usually taken by
pregnant women, has a side effect of
teratogenic effect on infants

A

Thalidomide strategy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

decides which drugs, biologics, and medical
devices are safe and efficacious and therefore
can be marketed.

A

FDA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

FDA reviews priority drugs in _________ and
standard drugs within ___________

A

six (6) months; ten (10) months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

antibiotics, cancer drugs, rx
drugs

A

Priority drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

otc drugs

A

Standard drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

developed a
web-based system that offers information about
ongoing clinical trials for a wide range of diseases
and conditions.

A

National Institute of Health (NIH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

agencies involved in the transparency and harmonisation of drug development

A
  • National Institute of Health (NIH)
  • International Conference on Harmonization (ICH)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Search for studies for particular diseases and
identify treatment centers that offer enrollment
into these studies.

A

National Institute of Health (NIH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

for the regulatory requirements for drug
approval

A

International Conference on Harmonization (ICH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

provide methods to ensure
simultaneous submission and rapid regulatory
approval in the world’s largest markets

A

International Conference on Harmonization (ICH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Minimize duplication of effort, improve
efficiency, increase quality and efficiency of
medical treatments worldwide

A

International Conference on Harmonization (ICH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

PROTECTION OF HUMAN SUBJECTS

A
  • Nuremberg Code
  • Declaration of Helsinki (1964)
  • Belmont Report (1978)
  • Code of Federal Regulations (CFR)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

judge the human experimentation conducted by
the Nazis in the middle of the twentieth century

A

Nuremberg Code

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

According to Nuremberg Code “__________ consent of the human subjects is
absolutely essential”

A

voluntary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

10 point statement/quotes which limits
permissible medical experimentation on human
subjects

A

consent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

re-emphasized protection of human subjects

A

Declaration of Helsinki (1964)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Developed by WMA (world medical
Association)

A

Declaration of Helsinki (1964)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Respect for individuals

A

Declaration of Helsinki (1964)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Right to be informed on decisions

A

Declaration of Helsinki (1964)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Recognition on Vulnerable groups

A

Declaration of Helsinki (1964)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

basic ethical principles underlying medical
research on human subjects

A

Belmont Report (1978)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Ethical principles involved in belmont report

A
  • Respect
  • Justice
  • beneficence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

designed to make the protection of human
subjects in all federal agencies uniform

A

Code of Federal Regulations (CFR)

42
Q

The drug approval process in the United States is
standardized by FDA review

A

DRUG APPROVAL PROCESS

43
Q

testing conducted either in
vitro or in animals. (harmful effects)

A

Preclinical testing

44
Q

Before filing an IND, the sponsor must have
developed a ___________ of the drug,
determined its acute and subacute toxicity, and
have sufficient information regarding chronic
toxicity to support the drug’s use in humans

A

pharmacologic profile

45
Q

Before filing an IND, the sponsor must have
developed a pharmacologic profile of the drug,
determined its ___________ toxicity, and
have sufficient information regarding ___________ to support the drug’s use in humans

A

acute and subacute; chronic
toxicity

46
Q

INVESTIGATIONAL NEW DRUG
APPLICATION (IND) is done before or after pre-clinical testing?

A

Done after pre-clinical testing

47
Q

the application by the study sponsor
(eg. pharmaceutical company, individual investigator
as sponsor-investigator) to the FDA to begin clinical
trials in humans.

A

IND

48
Q

Tests are reviewed by

A

FDA

49
Q

T/F: Informed consent is included in IND

A

T

50
Q

when will IND be not required

A
  • drug is marketed in the
    USA
  • Study is not reported to the FDA in support of
    a new indication
  • Study does not involve a different dose,
    route, patient population that increase risk to
    patients
  • IRB approval and informed consent are
    secured
  • Study will not be used to promote drug’s
    effectiveness for a new indication
51
Q

INVESTIGATIONAL NEW DRUG (IND) APPLICATION inclusions

A
  • Cover Sheet (Form 1571)
  • Table of Contents
  • Introductory statement
  • General Investigational Plan
  • Investigator’s brochure
  • Clinical protocol
  • Chemistry, manufacturing and control data
  • Pharmacology and toxicology data
  • Previous human experience
  • Additional information
52
Q

Four types of documents that may be used to amend
the IND

A
  • Protocol amendments
  • Information amendments
  • IND Safety Reports
  • Annual Reports
53
Q

Submitted when a
sponsor wants to change a previously submitted protocol or add a new study
protocol to an existing IND

A

Protocol amendments

54
Q

Submitted when
information becomes available that would not
be presented using a protocol amendment,
IND safety report, or annual report (e.g., new
chemistry data).

A

Information amendments

55
Q

reports clinical and
animal adverse reactions; reporting
requirements depend on the nature, severity,
and frequency of the experience.

A

IND Safety Reports

56
Q

describe the progress of the
investigation including information on the
individual studies, summary information of the
IND (summary of adverse experiences, IND
safety reports, preclinical studies completed in
the last year)

A

Annual Reports

57
Q

Suspected adverse reaction: An adverse
reaction for which there is evidence to suggest
a causal relationship between the drug and
the adverse event.

A

IND Safety Report

58
Q

An event that
results in any of the following outcomes:
death, a life-threatening adverse drug
experience, inpatient hospitalization or
prolongation of existing hospitalization, a
persistent or significant disability/incapacity, or
a congenital anomaly/birth defect.

A

Serious adverse event or serious
suspected adverse reaction:

59
Q

in IND Safety Report, FDA must be notified within __________ calendar days

A

15 calendar days

60
Q

An adverse
reaction that is not listed in the current labeling
for the drug product.

A

Unexpected adverse event or unexpected
suspected adverse reaction:

61
Q

Once submitted to the FDA, the IND will be
forwarded to the appropriate review division based
on the __________ of the product.

A

therapeutic category

62
Q

the IND and clinical trial will
be assigned to a review team that includes:

A
  • project manager
  • chemistry, manufacturing, and controls
    (CMC) reviewer
  • nonclinical pharmacology/toxicology
    reviewer
  • clinical reviewer,
63
Q

The FDA has _______ days after receipt of an IND
to respond to the sponsor.

A

30

64
Q

First use of the agent in humans

A

PHASE I

65
Q

Usually treat 20-80 patients (healthy volunteers)

A

PHASE I

66
Q

Used to determine the safety and toxicity of the
agent

A

PHASE I

67
Q

Evaluation of the effect of the drug on a subject who
does not have any pre-existing conditions

A

PHASE I

68
Q

PHASE I last an average of ________

A

six months to one year

69
Q

Small number of subjects who suffer from the
disease or condition that the drug is proposed to
treat

A

PHASE II

70
Q

Used to evaluate the efficacy of the agent.

A

PHASE II

71
Q

Usually treat between 100-200 patients

A

Phase II

72
Q

Phase II duration

A

2 years

73
Q

Used to further define the efficacy and safety of the
agent

A

PHASE III

74
Q

Comparison of the new agent is compared to
current therapy

A

PHASE III

75
Q

Usually multicenter studies

A

PHASE III

76
Q

Usually treat hundred to 3,000 patients

A

PHASE III

77
Q

Lasts about three years

A

PHASE III

78
Q

Considered “pivotal studies” basis for new drug
application product’s marketing approval

A

PHASE III

79
Q

the study of variations of
DNA and RNA characteristics as related to drug
response including effectiveness and adverse
effects

A

PHASE III

80
Q

phase wherein pharmacogenomics is already included

A

Pharmacogenomics

81
Q

impact of a certain genotype or phenotype relative
to response or adverse events

A

PHASE III

82
Q

NEW DRUG APPLICATION (NDA) is done after

A

Phase III trials

83
Q

Within ________ days, FDA will review the application (NDA) and
send the applicant an approval letter or complete
response letter

A

180

84
Q

Allows investigational drugs to be used for treatment
use in patients with serious or life-threatening
diseases where there is no other comparable or
satisfactory alternative therapy.

A

EXPANDED ACCESS TO INVESTIGATIONAL DRUGS
FOR TREATMENT USE

85
Q

those associated with
morbidity that has substantial impact on day-to-day
functioning

A

Serious conditions

86
Q

Authorization from FDA to charge for an IND in the
following conditions:

A

○ drug has a potential benefit
○ drug is effective/safe
○ RCT could not be conducted without
charging because the cost of the drug is
extraordinary to the sponsor.

87
Q

In priority review drug will potentially a significant
advance in medical care and sets a target to
review the drug within________ instead of the
standard ten (10) months

A

six (6) months

88
Q

Drugs can treat unmet
medical needs.

A

Fast Track Review

89
Q

Allows for early
approval of a drug for serious or life-threatening
illness that offers a benefit over current treatments.

A

Accelerated Approval Program

90
Q

allows for expedited
development and review of drugs which are
intended to treat serious conditions and which may
demonstrate substantial improvement over
available therapy

A

Breakthrough Therapy

91
Q

EXPEDITED REVIEW OF DRUGS

A

Priority Review
Fast Track Review
Accelerated Approval Program
Breakthrough Therapy

92
Q

Aka postmarketing studies after drug approval

A

PHASE IV

93
Q

Utilized by FDA when they determine that safety
measures are needed beyond the labeling to ensure
that a drug’s benefits outweigh its risks

A

RISK EVALUATION AND MITIGATION STRATEGIES
(REMS)

94
Q

size and population likely to use the drug,
seriousness of disease, expected benefits,
expected duration of treatment, seriousness of
events (known or potential), whether drugs is an
NME.

A

Factors to consider in determining the need for
REMS:

95
Q

REMS must be assessed for adequacy at least by

A

18 months, 3 years and 7 years after approval

96
Q

used for treatment of a rare
disease, affecting fewer than 200,000 people in the
USA, or one that will not regenerate enough
revenue to justify the cost of research and
development

A

THE ORPHAN DRUG ACT

97
Q

Committee formed to review proposed clinical trials
and the progress of such studies to ensure that the
rights and welfare of human subjects are protected.

A

INSTITUTIONAL REVIEW BOARD/INSTITUTIONAL
ETHICS COMMITTEE (IEC)

98
Q

liaison between IRB
and the sponsor

A

Principal Investigator (PI)

99
Q

After clinical trial, records must be maintained:

A

○ 2 years after approval of the NDA or
○ 2 years after FDA received notification that
investigation was discontinued.

100
Q

only individual who is not
aware of what the patient is receiving is the patient
him or herself.

A

Single-blind study

101
Q

the nurse, physician, and
patient are all unaware of what the patient is
receiving.

A

Double-blind study

102
Q

when the drug that arrives at
the pharmacy is already blinded.

A

Triple-blind study

103
Q
A

informatics (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions